Department Of Neurosciences, Addenbrookes Hospital

Cambridge, England

0 studies enrolling now · 2 studies all time

What they study most

Multiple Sclerosis, Relapsing-Remitting

Studies at this site

• Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two — Completed
• Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One — Completed